Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation

Xin Chen,1 Sarah Snanoudj-Verber,2 Laura Pollard,3 Yuhui Hu,1 Sara S. Cathey,3 Ritva Tikkanen,4 and Steven J. Gray1

Aspartylglucosaminuria (AGU) is an autosomal recessive lysosomal storage disease caused by loss of the enzyme aspartylglucosaminidase (AGA), resulting in AGA substrate accumulation. AGU patients have a slow but progressive neurodegenerative disease course, for which there is no approved disease-modifying treatment. In this study, AAV9/AGA was administered to Aga−/− mice intravenously (i.v.) or intrathecally (i.t.), at a range of doses, either before or after disease pathology begins. At either treatment age, AAV9/AGA administration led to (1) dose dependently increased and sustained AGA activity in body fluids and tissues; (2) rapid, sustained, and dose-dependent elimination of AGA substrate in body fluids; (3) significantly rescued locomotor activity; (4) dose-dependent preservation of Purkinje neurons in the cerebellum; and (5) significantly reduced gliosis in the brain. Treated mice had no abnormal neurological phenotype and maintained body weight throughout the whole experiment to 18 months old. In summary, these results demonstrate that treatment of Aga−/− mice with AAV9/AGA is effective and safe, providing strong evidence that AAV9/AGA gene therapy should be considered for human translation. Further, we provide a direct comparison of the efficacy of an i.v. versus i.t. approach using AAV9, which should greatly inform the development of similar treatments for other related lysosomal storage diseases.

INTRODUCTION

Aspartylglucosaminuria (AGU) is an autosomal recessive inherited lysosomal storage disease caused by the loss of functional aspartylglucosaminidase (AGA) enzyme. The AGA enzyme is required for the breakdown of glycoproteins within cellular lysosomes. Most individuals with a mutated AGA gene produce either small quantities of defective protein or an inactive precursor polypeptide, which results in the accumulation of the AGA substrate (aspartylglucosaminine, GlcNAc-Asn) in the lysosomes of all tissues and body fluids. The accumulated substrate GlcNAc-Asn is excreted in urine of patients in large quantities.

AGU is a slow but progressive and severe neurodegenerative disease characterized by intellectual disability, skeletal and motor abnormalities, and early mortality.1,2 The median lifespan of AGU patients is approximately 30 to 40 years. The major consequence of substrate accumulation is lysosomal hypertrophy that manifests as intellectual disability as well as additional symptoms including skeletal and joint abnormalities. AGU patients have developmental delays including delayed speech and impaired learning caused by progressive brain atrophy. By the third decade of life, patients have severe intellectual and physical disabilities and are highly dependent on supportive care.

There is no approved therapy for AGU patients that targets the root cause of the disease. A few approaches have been tested to treat AGU. Limited attempts at bone marrow transplantation (BMT) have not shown any benefit.3 Enzyme replacement therapy (ERT) has the potential to be an effective treatment, but peripheral administration does not adequately treat the central nervous system (CNS). In addition, manufacture of functional AGA with correct post-translational modifications is technically challenging, leading to significant challenges to implement ERT as a viable clinical treatment.4,5 Moreover, long-term ERT in a mouse model has been shown to induce immune responses, which abolish its therapeutic effects.4 More recently, treatment of patient fibroblasts in cell culture with small molecule compounds suggested that these substances may be suitable for AGU as a pharmacological chaperone (PC) mediated therapy,6,7 and its in vivo performance is being tested.

Over the last two decades, there have been numerous viral vector-based gene-therapy (GT) approaches tested for other rare inherited disorders and proved to be clinically therapeutic and safe, in some cases resolving the majority of patients’ symptoms.8 Recombinant adeno-associated viral vector type 9 (AAV9) has particularly been shown to be a safe and efficacious neurotropic vector to deliver transgenes to the CNS.9 These vectors are non-pathogenic, non-replicating, and transduce both dividing and non-dividing cells. Importantly, they are incapable of coding viral proteins and are primarily non-integrating, making them an ideal vector for gene delivery to the CNS.10 AAV9 mediates broad gene transfer across the entire
CNS in a way that translates from mice to larger animal models.\(^9\)\(^{–}\)\(^{19}\) Furthermore, AAV9 can be purified in large quantities at high concentrations for potential use in delivering a functional copy of a gene directly to the CNS using either an intravenous (i.v.)\(^{20}\)\(^{–}\)\(^{22}\) or intrathecal (i.t.)\(^{19}\)\(^{–}\) route of administration. The AAV9 vector is being utilized via i.v. administration in the Food and Drug Administration (FDA)-approved GT Zolgensma, for infants with spinal muscular atrophy (SMA). It is also being used in multiple GT clinical trials delivered by an i.t. route, including for giant axonal neuropathy (GAN), SMA, CLN6 Batten disease, and CLN3 Batten disease (ClinicalTrials.gov: NCT02362438, NCT03381729, NCT04273243, and NCT03770572, respectively).

For AGU patients, GT represents a reasonable and promising approach to provide a meaningful and long-term therapeutic benefit for this patient population. AGU is an attractive candidate for GT, as a portion of the expressed enzyme is secreted, and i.v. delivered AGA can be taken up by other cells via the mannose-6-phosphate pathway, potentially treating the condition in non-transduced diseased cell populations.\(^23\) There is also data on restoration of AGA expression in cell lines and animal models supporting an AGA GT approach.\(^24\)\(^{–}\)\(^{25}\)

The \(Aga^{−/−}\) mouse model is an accurate genetic model that mirrors the human AGU phenotype for efficacy testing. \(Aga^{−/−}\) mice do not have detectable AGA activity, have substrate GlcNAc-Asn accumulation in tissues and body fluids, and exhibit lysosomal hypertrophy in visceral organs, recapitulating the salient features of the human disease.\(^26\)\(^{–}\)\(^{28}\) By 5 months old, \(Aga^{−/−}\) mice have extensive morphological and no mRNA transcript. The study plan was as follows, which is outlined in Figure 1B: AAV9/AGA was administered to the \(Aga^{−/−}\) mice either i.v. with 200 fl of \(1 \times 10^{12}\) or \(2 \times 10^{13}\) vector genome (vg)/mouse or i.t. at 2 months old (pre-symptomatic) or 6 months old (early-symptomatic). Study readouts at each time point after dose administration or at specified age are listed from top to bottom.

Here, we present preclinical data to support the use of either i.v. – or i.t.-administered AAV9/AGA to rescue disease AGU phenotypes in a dose-dependent fashion, either before or after the onset of disease pathology in the \(Aga^{−/−}\) mouse model. This AAV9-based GT strategy has the potential to be broadly applied to correct other loss-of-function mutations that lead to CNS disorders.

**RESULTS**

To test whether we could use AAV9/AGA vector construct to rescue the phenotypes in the \(Aga^{−/−}\) mice, we created a recombinant AAV9 vector encoding a codon-optimized human AGA transgene (hAGAopt). The AAV9/AGA vector consists of AAV9 capsids that are packaged with the self-complementary (sc) AAV genome comprising a mutant AAV2 inverted terminal repeat (ITR) with the \(D\) element deleted (\(\Delta\) ITR), the CBh promoter (cytomegalovirus (CMV) enhancer, chicken beta actin promoter, and synthetic intron),\(^31\) hAGAopt DNA coding sequence, the bovine growth hormone polyadenylation (BGHpA) signal, and WT AAV2 ITR. (B) Study plan, duration, and readouts. Various doses of AAV9/AGA vector were administered either intravenously (i.v.) or intrathecally (i.t.) to the mice at 2 months old (pre-symptomatic) or 6 months old (early-symptomatic). Study readouts at each time point after dose administration or at specified age are listed from top to bottom.

Figure 1. AAV9/AGA Vector Construct to Express Human AGA and Study Plan of Mouse Experiment

(A) Schematic diagram of the AAV9/AGA gene transfer cassette comprising a mutant AAV2 inverted terminal repeat (ITR) with the \(D\) element deleted (\(\Delta\) ITR), the CBh promoter (CMV enhancer, chicken beta actin promoter, synthetic intron), codon-optimized human AGA DNA coding sequence (hAGAopt), the bovine growth hormone polyadenylation (BGHpA) signal, and WT AAV2 ITR. (B) Study plan, duration, and readouts. Various doses of AAV9/AGA vector were administered either intravenously (i.v.) or intrathecally (i.t.) to the mice at 2 months old (pre-symptomatic) or 6 months old (early-symptomatic). Study readouts at each time point after dose administration or at specified age are listed from top to bottom.
Cohorts of mice were injected when they were still pre-symptomatic at 2 months old or at 6 months old when they were at early stages of showing AGU-related pathology. AGA activity and AGA substrate GlcNAc-Asn levels were measured in both 2-month and 6-month cohorts at 1 week, 1 month, and 6 months post-injection, and at 12 and 18 months old. Behavioral tests were conducted in all treated animals at 14 months old, and brain imaging was conducted at 16 months old. All remaining mice were sacrificed at 18 months old for histology and immunohistochemistry (IHC) tests.

**AAV9/AGA GT Increases AGA Activity in Aga−/− Mice**

To examine the effects of AAV9/AGA vector delivery on levels of AGA protein in mice, serum AGA activity was measured longitudinally following a single dose of AAV9/AGA in mice treated at 6 or 2 months old. AGA activity and AGA substrate GlcNAc-Asn levels were measured in both 2-month and 6-month cohorts at 1 week, 1 month, and 6 months post-injection, and at 12 and 18 months old. Behavioral tests were conducted in all treated animals at 14 months old, and brain imaging was conducted at 16 months old. All remaining mice were sacrificed at 18 months old for histology and immunohistochemistry (IHC) tests.

**AAV9/AGA GT Reduces AGA Substrate GlcNAc-Asn Accumulation in Aga−/− Mice**

Absence of AGA enzymatic activity results in the accumulation of AGA substrate GlcNAc-Asn in the lysosomes of various tissues and body fluids. Large amounts of GlcNAc-Asn substrate can be readily detected in urine of AGU patients and is thereby used as a diagnostic biomarker. GlcNAc-Asn levels were measured longitudinally in the serum and urine at 1, 4, 24, 48, and 64 weeks and in CSF at 18 months old in both mouse cohorts treated with AAV9/AGA vector at either 6
or 2 months old (Figure 3). In the Aga\(\sim\) mice treated either with an i.v. or i.t. AAV9/AGA delivery, serum levels of GlcNAc-Asn were rapidly reduced close to undetectable levels by week 4 post-therapy and maintained at these low levels through week 64 in all treated cohorts except the i.t. low-dose cohort (Figures 3A and B). A similar trend was observed with the urinary excretion of GlcNAc-Asn (Figures 3C and 3D). We also found significant and dose-dependent decreases in the accumulation of GlcNAc-Asn in CSF collected at 18 months old (Figures 3E and 3F). Collectively, compared to control untreated Aga\(\sim\) mice, mice treated at 6 months or 2 months old i.v.
or i.t. with high doses of AAV9/AGA vector had rapid, sustained, and dose-dependent reductions of the AGA substrate GlcNAc-Asn in the serum, urine, and CSF, to levels similar to those found in the control Aga+/C0 mice.

AAV9/AGA GT Rescues Abnormal Behavior of Aga−/− Mice during the First 5 Minutes of Open-Field Tests

Based on the progressive nature of AGU, correction of GlcNAc-Asn substrate accumulation is expected to slow or even halt the neurodegeneration, resulting in an amelioration of the phenotypes seen in patients. To test this directly, mice treated at either 6 or 2 months old with AAV9/AGA were evaluated at 14 months old, when untreated Aga−/− mice show reduced activity in an open-field test. Contrary to previous publication,26 our colony of AGU mice displayed mild phenotypes overall, with limited tests showing statistically significant differences between Aga+/− and Aga−/− mice. The open-field test is a tool to assess novel environment exploration, anxiety-related behavior, and general locomotor activity.34 The mice were allowed to survey an open field, and we measured their distance traveled in the first 5 min as well as time spent with high movement versus time spent still. The first 5 min of the test session was chosen because it sufficiently captures the significant difference of locomotor activity between Aga−/− mice and their Aga+/− littermates (Figure S1). At 14 months old, Aga+/− mice were highly mobile, inspecting the new and unfamiliar surroundings, and spent less time immobile or stationary. In contrast, the untreated Aga−/− mice displayed lower exploratory behavior and traveled significantly shorter distances relative to their Aga+/− littermates (Figure 4).

Aga−/− mice that received an i.v.- or i.t.-delivered high dose of AAV9/AGA had improved activity in open-field tests when compared to the untreated Aga−/− mice, irrespective of whether the mice were treated at 6 months (Figures 4A–4C) or at 2 months old (Figures 4D–4F). Both cohorts of mice that had i.v. or i.t. delivery of high-dose AAV9/AGA showed a decrease in the time spent still (Figures 4C and 4F), increase in the time spent highly moving around (mobility)
AAV9/AGA GT Preserves Purkinje Cells in the Cerebellum in Aga⁻/⁻ Mice

Lysosomal hypertrophy as exhibited by cellular vacuolation in visceral organs of the Aga⁻/⁻ mice resembles human AGU histopathology. Neuronal, glial, and endothelial cells of the frontal cortex, cerebellum, brain stem, and spinal cord of the AGU mice become vacuolated around 6 months old and progressively worsen. By ten months, Aga⁻/⁻ mice have extensive loss of cerebellar Purkinje neurons, and by > 18 months old ~70%–80% of the Purkinje neurons in the cerebellar cortex are reportedly lost compared to their age-matched Aga⁺/⁺ littermates. We examined the cerebellar histopathology of GT-treated mice compared to their untreated Aga⁻/⁻ controls of the same age (Figure 5A). At 18 months old, hematoxylin and eosin (H&E) staining of cerebellum sections exhibited significant preservation of Purkinje neurons in both cohorts of mice, treated at 6 months or at 2 months old, compared to untreated Aga⁻/⁻ control mice, which exhibited loss of Purkinje neurons (Figures 5A–5C). These results were further confirmed with IHC staining of Purkinje cells in the cerebellum with an antibody against calbindin (Figure S2). Although we saw a less severe (~40%) loss of Purkinje neurons than what was previously reported (~70%–80% loss) for this Aga⁻/⁻ model, there was significant preservation of these neurons in mice that were treated at 6 months or 2 months old with the two
highest i.t. doses and with the low and high i.v. doses (Figures 5B and 5C).

**AAV9/AGA GT Reduces Gliosis in Aga−/− Mice**

Terminally ill Aga−/− mice reportedly show extensive gliosis in the brain.29 To establish when the onset of gliosis occurs and to what degree in the brains of our Aga−/− mice, we initially tested for gliosis at 2 and 6 months old in untreated mice to establish a baseline. Using glial fibrillary acidic protein (GFAP) staining, the 2-month-old Aga−/− mice did not have more gliosis in the cerebellum and midbrain compared to their Aga+/− littermates (Figures S3B, S3D, and S3E). By 6 months old, the Aga−/− mice displayed moderate but not significantly more gliosis in these brain regions compared to their Aga+/− littermates (Figures S3A, S3C, and S3E).

We then stained mouse brain for GFAP to evaluate for gliosis35 after necropsy of the AAV9/AGA-treated animals at 18 months old (Figure 6A). Compared to untreated Aga−/− control mice, the mice treated at both i.v. doses and the mice treated with the two highest i.t. doses at 6 months or at 2 months old had significantly reduced gliosis, comparable to that seen in the Aga+/− control animals (Figures 6B and 6C).

We also assessed GFAP staining within the isocortex, subcortex (hippocampus, thalamus, and hypothalamus), the MPM (midbrain, pons, and medulla), cervical spinal cord, and the lumbar spinal cord to assess for gliosis in these brain regions (Figure S4). Among those animals that received i.v. AAV9/AGA at 6 months old, there was a significant decrease in gliosis in the MPM (Figure S4C). Among those

---

**Figure 6. AAV9/AGA GT Significantly Reduces Gliosis in Aga−/− Mice**

(A–C) Various doses of AAV9/AGA vector were administered either i.t. or i.v. to Aga−/− mice at 6 months old (A and B) or 2 months old (C). At 18 months old, mouse brain was harvested for glial fibrillary acidic protein (GFAP) staining. Scale bars in (A) represent 500 μm. All data in (B) and (C) are presented as mean ± SEM. Asterisk (*) depicts significant difference (p < 0.05) by ordinary one-way ANOVA followed by Dunnett’s multiple-comparisons test compared to the untreated Aga−/− control. n = 6–7 in (B), and n = 7 in (C).
animals that received i.v. AAV9/AGA at 2 months old, there was a significant decrease in gliosis in the subcortex and MPM (Figures S4G and S4H). Among the animals that were treated at 2 months old with the highest i.t. dose, there was a significant decrease in gliosis in the subcortex, MPM, and cervical spinal cord (Figures S4G–S4I).

**AAV9/AGA GT Is Safe and Well-Tolerated in the Aga−/− Mice**

To assess the safety of the AAV9/AGA vector and to ensure there are no non-specific adverse effects on the animal model, brain size and brain weight were assessed in the control Aga+/− and Aga−/− mice injected with various doses of the AAV9/AGA vector, either i.v. or i.t. Sizes of the cerebellum, isocortex, striatum, and ventricle were measured at 16 months old in the animals using magnetic resonance imaging (MRI) (Figures S5A–S5D). There were no significant differences in the sizes of the brain regions between the untreated Aga−/−, treated Aga+/−, and Aga−/− littermates. Following necropsy at 18 months old, there were also no differences in whole-brain weight (Figure S5E). Additionally, it is worth noting that we were not able to reproduce previously published findings27,28 of MRI abnormalities in the Aga−/− mice.

Injection of AAV9/AGA vector with any dose, by either i.v. or i.t. route of delivery, did not reduce survival rate in either the pre-symptomatic or early-symptomatic mice, suggesting the AAV9/AGA GT is overall safe and well tolerated (Figure S6). This conclusion is further supported by the histopathological safety report (Supplemental Report) summarized by a blinded licensed veterinary pathologist who concluded that none of the microscopic findings are suggestive of adverse effects related to AAV9/AGA vector administration in Aga−/− mice.

**DISCUSSION**

Recombinant AAV9-mediated GT has been extensively used in preclinical and clinical studies for the treatment of CNS disorders. Efficacy with AAV9 has been demonstrated in numerous pre-clinical models of CNS disorders and in some clinical studies, using either an i.v. or i.t. route of administration. Here, we tested the feasibility and efficacy of an AAV9-based strategy to deliver the human AGA gene to the Aga−/− mouse, a model of AGU, an autosomal recessive inherited lysosomal storage disease. Of note, the study was designed as a comprehensive comparison of i.v. and i.t. routes of administration to treat AGU, which could serve as a model for the treatment of other lysosomal storage disorders with similar characteristics as AGU (i.e., CNS pathology and soluble lysosomal enzyme capable of cross-correction).

Apart from the main purpose of the study to evaluate the potential efficacy of AAV9/AGA, we also report additional characterization of the mouse model. In general, the phenotype in our colony of Aga−/− mice was notably less severe than was previously described26,29. Survival was not significantly impacted up to 18 months old, weight was unaffected up to 18 months old, pathology was milder than reported at 6 months and 18 months old, and we did not note the severe morbidity of mice as they approached 18 months old, as originally reported for the model. The caveat to this is that the Aga−/− mouse model was on a mixed background (the product of four distinct mouse strain backgrounds), which generated a mouse colony with four different fur colors (silver gray, light brown, dark brown, and black). Although a larger battery of behavioral tests were explored at different ages (rotarod, activity chamber, social novelty, and the Morris water-maze tests, data not shown), the mice generally showed a high degree of variability, and only the open-field test in aged mice was identified as a suitable behavioral outcome. The greatest phenotype affecting morbidity was extreme urinary retention as mice approached 20–21 months of age, which was the primary reason for our predetermined endpoint of 18 months old in our study design. The relatively mild phenotype in mice may be reflective of the protracted disease course in humans. Nevertheless, the mice display key features of the disease and our opinion is that they represent an adequate model to assess treatment efficacy and predict a translational benefit of AAV9/AGA.

The Aga−/− mice received a single injection of the AAV9/AGA before the emergence of disease pathology at 2 months old or at the early stage of disease pathology at 6 months old, in order to test whether the GT could restore AGA function and ameliorate the symptoms associated with AGU. Compared to their Aga+/− littermates, AAV9/AGA GT increased AGA activity to supraphysiological levels in the Aga−/− mice in a dose-dependent manner in serum with pre- and early-symptomatic intervention irrespective of the route of treatment. The activity levels were sustained in the GT-treated Aga−/− mice at the last instance of testing, up to 16 months after dosing, confirming stable expression of the human AGA transgene and enduring enzyme functionality. High levels of AGA activity detected in the brain tissue indicated efficient AGA enzyme biodistribution to the CNS following GT in the Aga−/− mice. The presence of AGA activity in the blood and peripheral tissues of the i.v.- and i.t.-dosed mice indicated that either i.v. or i.t. delivery of AAV9/AGA provides functional enzyme throughout the body. Of significance is the high levels of AGA activity in the blood and peripheral tissues following i.t. administration, which is consistent with prior observations that AAV9 distributes to peripheral organs following this route of administration.11,14,36

In the treated Aga−/− mice, we saw supraphysiological AGA enzyme activity within the CNS and throughout the entire body following GT, either from local expression or cross-correction by circulating enzyme. AGA enzyme activity is a key and relevant biochemical biomarker that is translatable to humans. These increased AGA enzyme levels correlated, in a dose-responsive fashion, with correction of another key translatable biochemical biomarker (AGA substrate GlcNAc-Asn), improved behavioral outcomes (movement in open field), and histopathological improvement (preservation of Purkinje neurons and reduced gliosis). Importantly, the totality of this data converges to an overall conclusion of a comprehensive rescue of the disease at the high dose, achievable via either an i.v. or i.t. route of administration of AAV9/AGA.
Although injection of AAV9/AGA by either route induces sustained circulating AGA levels that are over 100 times normal, this overabundance of AGA did not create any adverse consequences that we could discern. Compared to their WT littermates, Aga^{−/−} mice are reported to have poor survival, with only 40% surviving past the 20-month mark. In our hands, Aga^{−/−} mice have a median survival rate of over 18 months. There were no signs of morbidity seen in the treatment groups compared to normal Aga^{+/−} mice and untreated Aga^{−/−} mice. There were no differences in weight in treated versus untreated cohorts and no significant differences in survival. Further, treated mice displayed normalized movement patterns rather than any adverse signs. While observations of subtle toxic effects from AAV9/AGA are not completely ruled out, our data suggest a favorable long-term safety profile of AAV9/AGA at up to one year post-injection.

Both the i.t. and i.v. approaches provided a strong benefit to the Aga^{−/−} mice, and both approaches can translate to humans. A single 1 × 10^{11} vg i.t. dose provided clear biochemical, histological, and behavioral benefit to Aga^{−/−} mice, as did the higher 1 × 10^{12} vg i.t. or i.v. dose. A 5-fold lower i.t. dose (2 × 10^{10} vg) or a 5-fold lower i.v. dose (2 × 10^{11} vg) resulted in only a partial rescue. The highest 1 × 10^{12} vg i.t. dose did not provide any further benefit above the 1 × 10^{11} vg i.t. dose. Thus, our studies set a therapeutic target dose of either 1 × 10^{11} vg administered i.t. or 1 × 10^{12} vg (approximately 4 × 10^{13} vg/kg) administered i.v. Considering that a 10-fold lower dose can be administered i.t. versus i.v. with similar therapeutic effect, our conclusion would be to favor the i.t. route for human translation. Further, the apparent safety of a 10-fold higher (1 × 10^{12} vg) i.t. dose provides a favorable safety margin.

When considering human translation of the approach, a number of useful points can be derived from this study. First is a target dose, which in mice was 1 × 10^{11} vg administered i.t. If the dose is scaled by CSF volume, then this would equate to a dose of 4 × 10^{14} vg total in a human (assuming 0.035 mL of CSF in mice and 140 mL CSF in a human). The CSF volume of humans is relatively static after 3 years old, so this man phenotype. Mice were identified by toe clipping at post-natal 7 to 10 days and then randomized into treatment groups based on the ID

In conclusion, the results achieved in these preclinical studies demonstrate the efficacy and safety of AAV9/AGA and strongly support the clinical evaluation in AGU patients, pending the outcomes for further (and more rigorous) pre-clinical safety studies. While either an i.v. or i.t. approach would be predicted to work, we conclude that an i.t. approach should be favored. The conclusions from this study may translate to other AAV9-based gene replacement strategies for related neurological disorders.

**MATERIALS AND METHODS**

**Plasmid Design and Development**

We designed and developed the CBh-hAGAopt-BGHpa plasmid (Figure 1A) containing the transgene of a human AGA codon-optimized construct (hAGAopt). The DNA sequence was modified such that the final amino acid sequence is unchanged but there is a significant increase in expression levels of the heterologous gene. The transgene consists of a human AGA DNA coding sequence of 1,041 bp between an 800-bp CBh promoter and a 250-bp BGHpA signal. The gene regulatory elements (CBh promoter, BGHpA) are identical to the construct utilized and characterized in these publications, in mice, rats, pigs, and non-human primates. The CBh promoter and BGHpA are utilized for their small size and ability to drive strong expression, allowing for packaging into an scAAV vector.

**scAAV9/AGA Vector Preparation**

Research-grade AAV9/AGA vector for pre-clinical testing was manufactured at University of North Carolina Vector Core (UNC-VC). The established plasmid was packaged into sc AAV9 vector, which is 10–100 times more efficient at transduction compared to traditional single-stranded (ss) AAV vectors. The final purified product was dialyzed in phosphate-buffered saline (PBS) with an additional 212 mM NaCl and 5% D-sorbitol. Viral titers were determined by qPCR and confirmed by silver stain. The quality control summary of the AAV9/AGA vector is included in the Supplemental Information.

**Aga^{−/−} Mice**

All researches working with mice were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill (UNC-CH) or the University of Texas Southwestern (UTSW) Medical Center. An Aga^{−/−} mouse was generated and described in 1996 by Kaartinen et al. The mice have a targeted neomycin cassette insertion in exon 3, which leads to premature termination of the polypeptide at amino acid residue 103. The Aga^{−/−} mice do not have a detectable AGA activity and recapitulate the salient features of the human disease.

**Aga^{+/−}** breeders were obtained from Jackson Laboratories. A colony of these mice was established by breeding heterozygous female with homozygous male, and the natural course of the disease was monitored. In general, the disease progression of the colony was slower than was reported by Kaartinen et al. and Gonzalez-Gomez et al., but the disease was still apparent and consistent with the human phenotype. Mice were identified by toe clipping at post-natal 7 to 10 days and then randomized into treatment groups based on the ID
numbers assigned to them at genotyping. Genotyping was performed using genomic DNA extracted from clipped toe and three primers, AGA-10144 (5’-AGCGTGTTGCTGATGCTC-3’), AGA-10145 (5’-TCTGCAATGCTGTTGCTC-3’), AGA-Oimr7415 (5’-GCCA GAGGCACTTGTGTAAG-3’). A touchdown protocol with annealing temperature initially from 68°C to 64°C for 7 cycles and then 64°C for 27 cycles more was used for genotyping, which generated a WT band of 361 bp and mutant band of 240 bp.

Mouse Study Plan
The mouse study plan is summarized in Figure 1B. In brief, both male and female Aga−/− mice were injected either i.v. or i.t. at 2 months old (pre-symptomatic cohorts) or 6 months old (early-symptomatic cohorts). For i.v. administration, 200 μL of either a high (1 × 10^{12} vg/mouse) or low (2 × 10^{11} vg/mouse) dose of scAAV9/AGA vector was administered via tail vein. For i.t., 5 μL of either a very high (1 × 10^{12} vg/mouse), high (1 × 10^{11} vg/mouse), or low (2 × 10^{10} vg/mouse) dose of scAAV9/AGA vector was administered via lumen puncture. Injection volumes and vehicle composition was held constant across all dose levels. Serum and urine were collected for the measurement of AGA activity and AGA substrate at different time points post-injection. Behavioral tests and brain imaging were performed at 14 or 16 months old, respectively. Necropsy, histopathology, and toxicity evaluation were performed at the end of the experiment when mice reached 18 months old. Aga−/− mice were phenotypically normal, and age/sex-matched littermates were used as normal controls.

AGA Activity Assay
AGA activity assay was conducted using the method described previously with some modification. To measure serum AGA activity, 5 μL of each mouse serum was mixed with 20 μL of substrate buffer (pH 6.5) containing 1 mM of L-aspartic acid-7-amido-4-methylcoumarin (A1057-50 mg, Sigma-Aldrich) and 5 μL of reaction buffer containing 1× Hank’s balanced salt solution (HBSS) and 10 mM HEPES. This reaction was incubated at 37°C and 200 rpm for 1 h for samples from treated mice or 24 h for samples from untreated mice. The serum AGA activity was calculated against a standard curve and expressed as nmol/h/mL serum. To measure tissue AGA activity, approximately 25 mg of heart, liver, brain, or cervical spinal cord were mixed with 400 μL of deionized water and a 4.5-mm steel bead and physically lysed for 5 min at a speed of 25/s with a Tissuelyzer. After a freeze at −80°C overnight and thaw at room temperature, the samples were lysed again the same way and then centrifuged 3,000 × g at 4°C for 10 min. Tissue AGA activity was measured using 5 μL of supernatant of each sample. CSF AGA activity was measured using 2.5 μL of CSF. The AGA activity from both tissue and CSF was normalized against their respective protein concentration and expressed as nmol/h/mg protein.

AGA Substrate Assay
Analysis of the AGA substrate was conducted at Greenwood Genetics Center in a blinded fashion using coded samples. 15 μL of each sample, 3 μL of AGU internal standard (50 μg/mL), and 132 μL of 90% acetonitrile were added into one 1.5-mL centrifuge tube and vortexed immediately. Following the centrifugation at 13,000 rpm for 5 min, all supernatant was transferred into a 0.22-μm filter spin tube and centrifuged at 13,000 rpm for 1 min. The filtrate was then transferred from the filter tube to the polyspring insert in a wide-mouth screw cap vial and capped with a split liner.

Ultraprecision liquid chromatography (UPLC) separation utilized an Acquity I-class system equipped with a UPLC glycans BEH amide column (1.7 μm, 2.1 mm × 50 mm) with a VanGuard glycans BEH amide 1.7 μm guard column (5 × 2.1 mm, 1.7 μμ) all from Waters. Analytes were separated utilizing an elution gradient with water with 50 mM ammonium formate at pH 4.5 (mobile phase A) and acetonitrile (mobile phase B), a column temperature of 60°C, and a flow rate of 0.5 mL/min. A triple-quadrupole tandem mass spectrometer (Xevo TQ-S; Waters) was used in positive-ion detection mode. The tandem mass spectrometry (MS/MS) transition for the analytes was 336.14 > 204.05 and for the internal standard was 339.14 > 207.05. The capillary voltage was 2 kV, the cone voltage was 40 V, and the collision energy was 10 eV. The source temperature was 120°C, and the desolvation temperature was 60°C.

Open-Field Test
The open-field test consisted of an arena that was a 40 cm × 40 cm × 30 cm (L × W × H) plastic apparatus. The central square 20-cm × 20-cm region was designated as the central area, and the rest of the open field was considered as peripheral area. Mice were habituated to the experimental room for more than ten minutes prior to testing and then placed in the center of the arena at the beginning of the test period. As soon as the experimenter is out of view of the camera the testing period begins and last for 5 min. The apparatus was sprayed with 70% ethanol between each mouse, dried with paper towels, and left to air dry for 5 min. The video-tracking software EthoVision 12 (Noldus Information Technologies; Wageningen, the Netherlands) was used to measure the following parameters: total distance traveled, duration of mobility, and duration of immobility.

H&E and IHC Staining
Mouse tissues were drop fixed for 3 days in 10% phosphate-buffered formalin following perfusion of the mouse with PBS containing 1 U/mL heparin and transferred into 70% ethanol. Mouse brain, cervical spinal cord, and lumen spinal cord were paraffin processed, embedded, and cut into 5-μm sections either for H&E or IHC staining. For IHC, the sections were treated with antigen retrieval solution (H3300, Vector Laboratories) and then with 3% hydrogen peroxide (H₂O₂) to remove endogenous peroxidase activity. After incubation for 1 h at room temperature in blocking buffer containing 5% goat serum and avidin solution (SP2001, Vector Laboratories) in 1× PBS, the sections were incubated overnight at 4°C in primary antibody solution containing 5% goat serum and 1:4,000 rabbit anti-GFAP antibody (Z0334, Dako) or 1:200 rabbit anti-calbindin antibody (2173S, Cell Signaling) in 1× PBS and then incubated for 1 h at room temperature in second antibody solution containing 5% goat serum and 1:200 biotinylated anti-rabbit immunoglobulin
G (IgG) (BA-1000, Vector Laboratories) in 1× PBS. Color development was performed with a Vectastain ABC kit (PK-6100, Vector Laboratories) with 3,3′-diaminobenzidine tetrachloride (DAB) (TA-125-QHDX, Thermo Scientific) substrate and counterstaining with modified Mayer’s hematoxylin (72804, Richard-Allan Scientific). All stained slides were digitized with a ScanScope slide scanner (Aperio Technologies), and scanned slides were viewed with ImageScope software package (version 10.0; Aperio Technologies). GFAP staining intensity was quantified with Halo software package (Halo2.2; Indica Labs).

MRI

T2 weighted images were acquired with a 3D RARE sequence on a Bruker 9.4 T animal MRI scanner. The sequence parameters are as follows: TR = 3000 ms, TE = 56 ms, RARE factor = 8, matrix size 133 × 96 × 96, voxel size = 0.15 × 0.15 × 0.15 mm³, and total duration = 39.06 min. During the scan, the animals were anesthetized by inhaling ~2% isoflurane and oxygen mixture through a nose cone. They were placed on a custom-made cradle in a prone position, and their heads were fixed using tooth and ear bars. Body temperature and respiratory rate were continuously monitored and maintained within normal ranges over the duration of the scan (37 ± 0.5 °C, 80 ± 20 bpm, respectively). The T2 weighted images were segmented using a fully automated rodent brain MR image processing pipeline.43 Based on the segmentation masks, the volumes of the cerebellum, isocortex, striatum, and ventricle were calculated and compared between the six groups. Operators and image analyzers were blind to genotype and treatment, which was conducted by the Animal MRI (CAMRI) and Biomedical Research Imaging Center (BRIC) at UNC.

Statistical Analysis

All data in this paper were presented as mean ± SEM, analyzed, and graphed using GraphPad Prism software (version 7.04, GraphPad Software). Student’s unpaired t test was used for two-group comparison and one-way ANOVA followed by Dunnett’s multiple comparisons test compared to the untreated AGA−/− control was used for equal or more-than-three-group comparison. Statistical significance was set as p < 0.05.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.ymthe.2020.11.012.

ACKNOWLEDGMENTS

This study was supported by the Rare Trait Hope Fund (USA), the UNC TraCS Institute (USA, 550KR121511), and AFM-Téléthon (France, Award 19715) to S.J.G. We thank Jackson Laboratories for providing the AGA−/− breeders, the UNC Vector Core facility for producing some vectors used in these studies, and Greenwood Genetics Center for performing the AGA substrate assays. We thank the members at the UNC Center for Animal MRI (CAMRI) and Biomedical Research Imaging Center (BRIC) for technical assistance, supported in part by the Bowles Center for Alcohol Studies (P60 AA011605), the Lineberger Comprehensive Center (P30 CA016086), and the Carolina Institute for Developmental Disabilities (U54 HD079124). We also acknowledge Dr. Thomas Dong for his help in sample preparation, Dr. Mary Wight-Carter for her toxicity evaluation and histopathological safety report, Dr. Anna Azvolinsky for her support in manuscript preparation, and Dr. Stuart Cobb for his insightful manuscript review.

AUTHOR CONTRIBUTIONS

X.C. and S.J.G. designed the experiments, coordinated studies with collaborators and core facilities, and wrote the manuscript. X.C., S.S.-V., L.P., and Y.H. performed the experiments. S.S.C. served as a consultant on this project. X.C. analyzed all data and prepared all figures for the manuscript. L.P. and Y.H. helped writing the Materials and Methods section. R.T. advised the project, shared protocols, and reviewed the manuscript. S.J.G. oversaw all activities related to the project and acquired all funding for the work.

DECLARATION OF INTERESTS

S.J.G. has received patent royalties for intellectual property (IP) licensed to Asklepios Biophama, but this IP was not used in this study. S.J.G. is an inventor of the AGA vector design and has received patent royalties on this technology from Neurogene.

REFERENCES

1. Arvio, M., and Mononen, I. (2016). Aspartylglucosaminuria: a review. Orphanet J. Rare Dis. 11, 162.
2. Arvio, P., and Arvio, M. (2002). Progressive nature of aspartylglucosaminuria. Acta Paediatr. 91, 255–257.
3. Arvio, M., Sauna-Aho, O., and Peippo, M. (2001). Bone marrow transplantation for aspartylglucosaminuria: follow-up study of transplanted and non-transplanted patients. J. Pediatr. 138, 288–290.
4. Dunder, U., Kaartinen, V., Valtonen, P., Viinäinen, E., Kosma, V.M., Heisterkamp, N., Groffen, J., and Mononen, I. (2000). Enzyme replacement therapy in a mouse model of aspartylglucosaminuria. FASEB J. 14, 361–367.
5. Dunder, U., Valtonen, P., Kelo, E., and Mononen, I. (2010). Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglucosaminuria mice. J. Inherit. Metab. Dis. 33, 611–617.
6. Ranning, A., Güçler, C., Rezvani, I., Gray, S.J., and Tikkanen, R. (2016). Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria. Sci. Rep. 6, 37583.
7. Ranning, A., Schiff, M., and Tikkanen, R. (2018). Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 668–675.
8. Naldini, L. (2015). Gene therapy returns to centre stage. Nature 526, 351–360.
9. Sazava, J., Nohr, R.J., and Pereira de Almeida, L. (2016). Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. J. Control. Release 241, 94–109.
10. Choudhury, S.R., Hudry, E., Maguire, C.A., Sena-Esteves, M., Breakefield, X.O., and Grandi, P. (2017). Viral vectors for therapy of neurologic diseases. Neuropharmacology 120, 63–80.
11. Bailey, R.M., Armao, D., Nagabhushan Kalburgi, S., and Gray, S.J. (2018). Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol. Ther. Methods Clin. Dev. 9, 160–171.
12. Karumuthil-Melethil, S., Marshall, M.S., Heindel, C., Jakubauskas, B., Bongarzone, E.R., and Gray, S.J. (2016). Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant. J. Neurosci. Res. 94, 1138–1151.
13. Federici, T., Taub, J.S., Baum, G.R., Gray, S.I., Grieger, J.C., Matthews, K.A., Handy, C.R., Passini, M.A., Samulski, R.J., and Boulis, N.M. (2012). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 19, 852–859.

14. Gray, S.J., Nagabhushan Kalbargi, S., McCown, T.J., and Jude Samulski, R. (2013). Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450–459.

15. Snyder, B.R., Gray, S.J., Quach, E.T., Huang, J.W., Leung, C.H., Samulski, R.J., Boulis, N.M., and Federici, T. (2011). Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum. Gene Ther. 22, 1123–1135.

16. Masamizu, Y., Okada, T., Kawasaki, K., Ishishishi, H., Yuasa, S., Takeda, S., Hasegawa, I., and Nakahara, K. (2011). Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9. Neuroscience 193, 249–258.

17. Boucher, T., Colle, M.A., Wakeling, E., Dubrel, L., Fyfe, J., Briot-Nivard, D., Macquegneau, M., Raoul, S., Cherly, Y., Astord, S., et al. (2013). scAAV intracerebral delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum. Gene Ther. 24, 670–680.

18. Hauriet, V., Marcò, S., Ribera, A., Garcia, M., Rizo, A., Villacampa, P., Ayuso, E., Añor, J., Andaluz, A., Pineda, M., et al. (2013). Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J. Clin. Investig. 123, 3524–3527.

19. Samaranich, L., Salegio, E.A., San Sebastian, W., Kells, A.P., Bringas, J.R., Forsayeth, J., and Bankiewicz, K.S. (2013). Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24, 526–532.

20. Gray, S.J., Mataagne, V., Bachaboina, L., Yadav, S., Ojeda, S.R., and Samulski, R.J. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058–1069.

21. Duque, S., Joussenret, B., Riviere, C., Marais, T., Dubrel, L., Douar, A.M., Fyfe, J., Moullet, P., Colle, M.A., and Barkats, M. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187–1196.

22. Fouet, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., and Kaspar, B.K. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59–65.

23. Sands, M.S., and Davidson, B.L. (2006). Gene therapy for lysosomal storage diseases. Mol. Ther. 13, 839–849.

24. Pelton, M., Kytiala, A., Heinenon, O., Rapola, J., Paunio, T., Revu, I., Peltonen, L., and Jalkano, A. (1998). Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminidase (AGU) mouse. Gene Ther. 5, 1314–1321.

25. Harke, S., Laine, M., and Jalkano, A. (2003). Aspartylgluconamidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder. J. Gene Med. 5, 472–482.

26. Kaartinen, V., Mononen, I., Vonck, J.W., Noronkoski, T., Gonzalez-Gomez, I., Heisterkamp, N., and Gronfen, J. (1996). A mouse model for the human lysosomal disease aspartylglucosaminidase. Nat. Med. 2, 1375–1381.

27. Jalanko, A., Tenhunen, K., McKinney, C.E., LaMarca, M.E., Rapola, J., Autti, T., Joensuu, R., Manninen, T., Hipila, I., Ikonen, S., et al. (1998). Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients. Hum. Mol. Genet. 7, 265–272.

28. Tenhunen, K., Uusitalo, A., Autti, T., Joensuu, R., Kettnen, M., Kauppinen, R.A., Ikonen, S., LaMarca, M.E., Hallia, M., Ginnis, E.L., et al. (1998). Monitoring the CNS pathology in aspartylglucosaminuria mice. J. Neurophil. Exp. Neurol. 57, 1154–1163.

29. González-Gómez, I., Mononen, I., Heisterkamp, N., Groffen, J., and Kaartinen, V. (1998). Progressive neurodegeneration in aspartylglycosaminuria mice. Am. J. Pathol. 153, 1293–1300.

30. Kaartinen, V., Mononen, I., Gonzalez-Gomez, I., Noronkoski, T., Heisterkamp, N., and Groffen, J. (1998). Phenotypic characterization of mice with targeted disruption of glycosylasparaginase gene: a mouse model for aspartylglycosaminuria. J. Inherit. Metab. Dis. 21, 207–209.

31. Gray, S.J., Foti, S.B., Schwartz, J.W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Eblen, M.D., Zylka, M.J., McCown, T.J., and Samulski, R.J. (2011). Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143–1153.

32. Tikkanen, R., Peltola, M., Oinonen, C., Rouvinen, J., and Peltonen, L. (1997). Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase. EMBO J. 16, 6684–6693.

33. Mononen, I.T., Kaartinen, V.M., and Williams, J.C. (1993). A fluorometric assay for glycosylasparaginase activity and detection of aspartylglycosaminuria. Anal. Biochem. 208, 372–374.

34. Prut, L., and Belzung, C. (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463, 3–33.

35. Yang, Z., and Wang, K.K. (2015). Gial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 38, 364–374.

36. Sinnett, S.E., Hector, R.D., Gadalla, K.K.E., Heindel, C., Chen, D., Zaric, V., Bailey, M.E.S., Cobb, S.R., and Gray, S.J. (2017). Improved MECP2 gene therapy extends the survival of Mecp2-null mice without apparent toxicity after intracisternal delivery. Mol. Ther. Methods Clin. Dev. 5, 106–115.

37. Bleyer, W.A., and Dedrick, R.L. (1977). Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat. Rep. 61, 703–708.

38. McCarty, D.M., Fu, H., Monahan, P.E., Toulson, C.E., Naik, P., and Samulski, R.J. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112–2118.

39. McCarty, D.M., Monahan, P.E., and Samulski, R.J. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248–1254.

40. Gray, S.J., Choi, V.W., Asokan, A., Haberman, R.A., McCown, T.J., and Samulski, R.J. (2011). Production of recombinant adeno-associated viral vectors and use in vitro and in vivo administration. Curr. Protoc. Neurosci. 57, 4.17.1–4.17.30.

41. Christakis, D.A., Ramirez, J.S., and Ramirez, J.M. (2012). Overstimulation of newborn mice leads to behavioral differences and deficits in cognitive performance. Sci. Rep. 2, 546.

42. Budin, F., Hoogstoel, M., Reynolds, P., Grauer, M., O’Leary-Moore, S.K., and Oguz, I. (2013). Fully automated rodent brain MR image processing pipeline on a Mids server: from acquired images to region-based statistics. Front. Neuroinform. 7, 15,